Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, Supriya Lifescience has informed that it enclosed statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended March 31, 2023 in the prescribed format. Further, it has confirmed that there is no deviation or variation in the utilisation of IPO proceeds from the objects stated in the prospectus dated December 21, 2021.
The above information is a part of company’s filings submitted to BSE.
